Efficacy and Safety of Anlotinib Monotherapy as Third-Line Therapy for Elderly Patients with Non-Small Cell Lung Cancer: A Real-World Exploratory Study

PURPOSE: The present study was to investigate the real-world efficacy and safety of anlotinib monotherapy as third-line therapy for elderly patients with advanced non-small cell lung cancer (NSCLC). METHODS: A total of 83 elderly patients (>65 years) with NSCLC who were progressed at least two li...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiang, Hong-Tao, Li, Wei, Zhang, Biao, Gong, Qiang, Qie, Hai-Ling
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8572099/
https://www.ncbi.nlm.nih.gov/pubmed/34754233
http://dx.doi.org/10.2147/IJGM.S334436

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8572099/
https://www.ncbi.nlm.nih.gov/pubmed/34754233
http://dx.doi.org/10.2147/IJGM.S334436

Ejemplares similares